Format

Send to

Choose Destination
Prog Neuropsychopharmacol Biol Psychiatry. 2018 Aug 30;86:294-300. doi: 10.1016/j.pnpbp.2018.04.008. Epub 2018 Apr 20.

Genetic imaging study with [Tc-99m] TRODAT-1 SPECT in adolescents with ADHD using OROS-methylphenidate.

Author information

1
Deparment of Child and Adolescent Psychiatry, Dokuz Eylul University, Izmir, Turkey. Electronic address: pekcanlara@yahoo.com.
2
Deparment of Nuclear Medicine, Dokuz Eylul University, Izmir, Turkey.
3
Department of Psychology, H. Kalyoncu University, Gaziantep, Turkey; Medical School of Houston, Center for Neurobehavioral Research on Addictions, University of Texas, Houston, TX, USA.
4
Deparment of Molecular Biology and Genetics, Dokuz Eylul University, Izmir,Turkey.
5
Dr.Behçet Uz Pediatrics, Pediatric Surgery Research andTraining Hospital, Deparment of Child and Adolescent Psychiatry, Izmir, Turkey. Electronic address: handanozek@yahoo.com.
6
Deparment of Child and Adolescent Psychiatry, Dokuz Eylul University, Izmir, Turkey.
7
Department of Computer Engineering, Izmir University of Economics, Izmir, Turkey.
8
Deparment of Psychiatry, EgianUniversity, Izmir, Turkey.
9
Department of Psychiatry, Federal University of Rio Grande do Sul, Brazil; ADHD Program, Hospital de Clínicas de Porto Alegre, Brazil.

Abstract

AIM:

To examine theeffects on the brain of 2-month treatment withamethylphenidate extended-release formulation (OROS-MPH) using [Tc-99m] TRODAT-1SPECT in a sample of treatment-naïve adolescents with Attention Deficit/Hyperactivity Disorder (ADHD). In addition, to assess whether risk alleles (homozygosity for 10-repeat allele at the DAT1 gene were associated with alterations in striatal DAT availability.

METHODS:

Twenty adolescents with ADHD underwent brain single-photon emission computed tomography (SPECT) scans with [Tc-99m] TRODAT-1 at baseline and two months after starting OROS-MPH treatment with dosages up to 1 mg/kg/day. Severity of illness was estimated using the Clinical Global Impression Scale (CGI-S) and DuPaul ADHD Rating Scale-Clinician version (ARS) before treatment,1 month and 2 months after initiating OROS-MPH treatment.

RESULTS:

Decreased DAT availability was found in both the right caudate (pretreatment DAT binding: 224.76 ± 33.77, post-treatment DAT binding: 208.86 ± 28.75, p = 0.02) and right putamen (pre-treatment DAT binding: 314.41 ± 55.24, post-treatment DAT binding: 285.66 ± 39.20, p = 0.05) in adolescents with ADHD receiving OROS-MPH treatment. Adolescents with ADHD who showed a robust response to OROS-MPH (n = 7) had significantly greater reduction of DAT density in the right putamen than adolescents who showed less robust response to OROS-MPH (n = 13) (p = 0.02). However, between-group differences by treatment responses were not related with DAT density in the right caudate. Risk alleles (homozygosity for the 10-repeat allele of DAT1 gene) in the DAT1 gene were not associated with alterations in striatal DAT availability.

CONCLUSION:

Two months of OROS-MPH treatment decreased DAT availability in both the right caudate and putamen. Adolescents with ADHD who showed a robust response to OROS-MPH had greater reduction of DAT density in the right putamen. However,our findings did not support an association between homozygosity for a 10-repeat allele in the DAT1 gene and DAT density, assessedusing[Tc-99m] TRODAT-1SPECT.

KEYWORDS:

ADHD; DAT1 gene; OROS-methylphenidate; [Tc-(99m)] TRODAT-1 SPECT

PMID:
29684537
DOI:
10.1016/j.pnpbp.2018.04.008
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center